This site is intended for healthcare professionals
Drug information


Read time: 14 mins
Last updated: 25 Mar 2020
Published: 02 Jun 2020

4.1 Therapeutic indications

Amisulpride is indicated for the treatment of acute and chronic schizophrenic disorders with:

• positive symptoms (such as delusions, hallucinations, thought disorders, hostility, suspiciousness), and/or

• negative symptoms (deficit syndrome) such as blunted affect, emotional and social withdrawal

This includes patients with predominant negative symptoms.

Register free for full access to




The drug SPC information (indications, contra-indications, interactions, etc), has been developed in collaboration with eMC ( Medthority offers the whole library of SPC documents from eMC.

Medthority will not be held liable for explicit or implicit errors, or missing data.

Reporting of suspected adverse reactions 

Drug Licencing

Drugs appearing in this section are approved by UK Medicines & Healthcare Products Regulatory Agency (MHRA), & the European Medicines Agency (EMA).